New drugs for malaria prevention (and the problems with the old ones)

Malaria is a parasitic disease causing 228 million clinical infections and 405,000 deaths annually in endemic countries1, and is a constant threat to travelers from other countries who lack any immunity to malaria. Despite a supply of artemisinin combination therapies and bed nets to treat malaria and prevent transmission, and a partially effective vaccine in the periphery, these tools alone are unlikely to allow regional malaria elimination in the near future.


In the travel medicine market, antimalarial drugs have been only partially adequate.They simply have not protected against all species of the parasite in all parts of the world. In addition, they have required busy travelers to adhere to daily dosing or complicated schedules for post-exposure prophylaxis. 60° Pharmaceuticals (60P) is proud to be providing new and better solutions.

The malaria threat – Prophylaxis

  • Over 3 billion people live in areas at risk of malaria transmission in 97 countries and territories1
    • Annually over 228 million cases and more than 405,000 deaths1
  • 125 million travelers to endemic regions per annum
    • 10,000-plus reported traveler cases of malaria
    • Prophylactics utilized by 78% of Europeans and 48% of US citizens when traveling to endemic countries
    • US$270 million per annum in global sales of malaria prophylactic drugs
World distribution of malaria map
World Distribution of Malaria
Reference 1.World Health Organization. Fact sheet: world malaria report 2019. Geneva, Switzerland: World Health Organization; 2019.

Annual deaths from malaria globally


Travelers to endemic regions per annum


Dengue infections per year


1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036